Noninvasive treatment of tumors that regrow in lung cancer patients is now more possible than ever using CyberKnife® technology. Havertown-based Philadelphia CyberKnife together with Drexel University College of Medicine recently completed a study demonstrating the efficacy of this approach for patients experiencing a recurrence or spread of a lung tumor.
In the last decade, treatment for these diagnoses has progressed using chemotherapy, surgery and external beam radiation therapy, but patients often experience decreased lung functionality following these treatments. The Philadelphia CyberKnife team presented their study at the 2013 National Radiosurgery Society meeting as one of the first of its kind to evaluate this method of treatment for recurrence.
The method uses stereotactic body radiation therapy for recurrent lung cancer patients who have been previously treated with conventional radiation therapy, a process called reirradiation. Results from the study demonstrated patients who received SBRT reirradiation experienced good tumor control at that site and fewer long-term side effects over a three-year period compared with other series of reirradiation.
The U.S. Preventive Services Task Force (USPSTF) recently released a recommendation in favor of CT lung cancer screening for long-term smokers.
Though still pending finalization, the recommendation applies to current and heavy smokers between 55 and 79 and could be a huge step in diagnosing high-risk patients sooner.
The U.S. Preventive Services Task Force is an independent, volunteer panel of national experts in prevention and evidence-based medicine. The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services and preventive medications.
Since opening in 2006, Philadelphia CyberKnife physicians have contributed cutting edge research on the applications of stereotactic body radiation therapy and CyberKnife® treatment. Two studies developed by physicians at our center on SBRT treatment for lung cancer were presented earlier this year at the Radiosurgery Society’s annual meeting. Read more about this research here.
To read more about the recommendation, view the draft for public comment.
Each October, the breast cancer community gathers to raise awareness and garner support for the fight against breast cancer. The American Cancer Society estimates 232,340 cases of breast cancer will be diagnosed in 2013 and one in eight women will develop breast cancer during her lifetime.
During Breast Cancer Awareness Month, October 13 is dedicated to awareness of metastatic breast cancer, a condition where cancer has spread from the breast to another part of the body. Metastases are named for the location where cancer develops, not where it spreads. While metastatic cancers are difficult to monitor, cancer types often spread in similar patterns. Read more about metastases here.
The Metastatic Breast Cancer Network (MBCM) is a hub for educational materials, fundraising and support for metastatic breast cancer. The MBCM hosts an annual conference and events across the nation. To read more about the MBCM, visit their website.
Philadelphia CyberKnife treats certain metastases with stereotactic body radiation therapy using CyberKnife® technology. Our center is proud to provide a treatment option to breast cancer patients whose cancer has spread to other areas such as the brain or lungs. Watch an overview of the CyberKnife treatment process here.
The American Cancer Society estimates lung cancer will be detected in nearly 220,000 people this year. The disease, ranked as the most common cancer diagnosis worldwide, kills more people annually than breast, colon and pancreatic cancers combined.
While surgery or external-beam radiation therapy is considered a standard treatment for lung cancer, patients who are in poor general health or suffer from chronic pulmonary disease, like emphysema, may need to consider other options.
Our center offers a noninvasive form of treatment for lung cancer called stereotactic body radiation therapy (SBRT). During the procedure, precisely targeted radiation beams are delivered directly to a patient’s tumor with sub-millimeter accuracy, minimizing damage to surrounding healthy tissue.
Though primarily used to treat benign and malignant tumors, stereotactic radiosurgery can also treat additional medical conditions, including a rare nerve disorder, trigeminal neuralgia (TN).
Excruciating facial pain triggered by everyday activities such as chewing, talking or swallowing characterizes the debilitating condition. TN can often be mistaken for a dental problem, since the disorder usually causes sharp pain in the jaw. Diagnosis sometimes takes several years, as patients may undergo root canals or tooth extractions in an attempt to relieve their pain.
TN can occur when a blood vessel compresses the fifth cranial nerve, one of the largest nerves in the head. Many times, no cause can be found. As the pain intensifies, patients find themselves unable to predict what may trigger the next episode. Treatment typically involves powerful painkilling drugs or other antidepressant or anticonvulsive medication.
Using CyberKnife® technology, our center performs stereotactic radiosurgery, a noninvasive method of treating certain types of tumors and conditions like TN with high-dose radiation beams delivered in five or fewer procedures. To treat a patient with TN, the CyberKnife delivers very precise radiation beams to a targeted segment of the trigeminal nerve to interrupt pain-causing fibers. The pinpoint accuracy of the procedure spares healthy tissue and allows us to treat difficult-to-reach targets without surgery or sedation.
TN treatment is typically a one-time, outpatient procedure and is completed within an hour. TN does not have a cure, but pain can be reduced or eliminated in 85 to 90 percent of patients who are treated with stereotactic radiosurgery.
When someone is diagnosed with cancer, determining the stage of the cancer is an important next step. Staging describes the extent or severity of a person’s cancer, which helps doctors determine the best course of treatment and a prognosis.
Common Staging Procedures and Types:
The information in this post was pulled from the American Cancer Society. For more information on cancer staging, visit The American Cancer Society or talk to your doctor.
This month, Philadelphia CyberKnife celebrates its seventh year of operations as a service of Delaware County Memorial Hospital, part of the Crozer-Keystone Health System. Our center was the first provider of stereotactic radiosurgery (SRS) treatment in the Philadelphia region, and we’ve treated nearly 2,000 patients with the advanced procedure using CyberKnife® technology.
Through research spearheaded by our center’s team, Philadelphia CyberKnife has earned a global reputation as a leader in the field of stereotactic radiosurgery. More than half of the patients treated at Philadelphia CyberKnife have traveled from areas outside our center’s service area, including patients from the United Kingdom, Australia and across the U.S.
“As the first CyberKnife center in the Philadelphia area, we have had the opportunity to play an instrumental role in developing and demonstrating applications for this technology through our research efforts,” said Dr. John Lamond, Philadelphia CyberKnife associate medical director. “Our priority is to continuously investigate the best strategies in cancer care to better serve our patients and improve treatment outcomes.”
Brain tumors are among the most frequently treated diseases at our center, making up a quarter of total cases. In January, Philadelphia CyberKnife began collaborating with physicians in Crozer-Keystone’s HAN Neurosurgical Practice Associates practice to provide joint consultations for brain tumor patients when planning treatment. The new collaborative effort has led to a more comprehensive multidisciplinary approach to patient care in a timely fashion.
CyberKnife usually treats brain tumors in one session, but treatment may require up to five sessions depending on the individual diagnosis. During treatment, highly focused radiation beams are delivered to tumors with sub-millimeter accuracy. The outpatient procedure does not require incisions or sedation.
“Patients typically experience few to no side effects following treatment,” Dr. Lamond said. “For some patients, choosing CyberKnife can mean a decreased risk of harming healthy brain tissue surrounding a tumor as compared with other treatment methods. Additionally, the ability to immediately return to their daily routines appeals to many of our patients.”
In addition to treating brain tumors, Philadelphia CyberKnife treats malignant and benign tumors in the prostate, spine, lung, liver, pancreas, kidney and eyes. Our center is currently finalizing clinical studies on brain, lung and gynecological cancers.
The CyberKnife nurse provides clinical support and care coordination for patients. This includes assisting the CyberKnife radiation oncologist during patient consultation, educating patients and families in preparation for treatment, managing symptoms and coordinating appointments and treatment schedules.
Michael Good serves as our center’s CyberKnife nurse navigator. We are so grateful for the support and guidance he provides to our patients and their loved ones!
Delaware County Memorial Hospital is recognized for its wide spectrum of acute and specialty services. Established in 1927, the not-for-profit hospital features a Level II-A Neonatal Intensive Care Nursery, a Center for Breast Health honored by the National Accreditation Program for Breast Centers, along with many other services. It is certified by The Joint Commission as a primary stroke center, in hip and knee surgery, and for its breast cancer care.
The hospital provides other notable services, including a Wound Healing and Hyberbaric Medicine center, an Emergency Department with a 14-bed Critical Intensive Care Unit, a comprehensive Maternity Center and a full range of musculoskeletal services.
The not-for-profit hospital is a founding member of the Crozer-Keystone Health System, a community-focused health care system dedicated to providing high-quality, cost-effective patient care and educating both current and future physicians and caregivers. The system comprises five hospitals, several outpatient centers and a sports club. It is the largest health care provider in Delaware County.
In 2006, Delaware County Memorial Hospital partnered with Philadelphia CyberKnife, which was the first provider of CyberKnife treatment in the Philadelphia area. We are so proud to be affiliated with such an accomplished hospital! For more information on Delaware County Memorial Hospital, click here.
Dr. John Lamond, associate medical director of Philadelphia CyberKnife, has more than 20 years of experience treating tumors throughout the body. As an active clinical researcher, Dr. Lamond has special interests in brain and lung cancers and has served as the principal investigator on several studies. Read about results from a recent study he co-authored here.
Learn more about his experiences at Philadelphia CyberKnife.
What first drew you to radiation oncology?
My mother was diagnosed with breast cancer during my first year of medical school. She chose breast-conserving treatment with lumpectomy and radiation, which was rather new at that time. This sparked my interest in oncology, especially newer treatment options, and it has lasted to this day.
What do you like best about your job?
I love taking on a challenging case. Having a tool like CyberKnife® allows us to help certain patients with tumors that were untreatable in the past. It is rewarding to know we have improved our ability to treat certain patients, such as early-stage lung cancer patients who are unable to undergo surgery.
Describe one of your most memorable experiences since you began working at Philadelphia CyberKnife.
We treated a young man with a mesenchymal chondrosarcoma, an aggressive rare brain tumor. Using a combination of surgery, chemotherapy, external radiation and CyberKnife treatment, he was cured six years ago.
What do you feel is the most important thing that Philadelphia CyberKnife offers?
I think the hope CyberKnife provides patients who would formerly be told their tumors are inoperable or untreatable is most important.
How do you stay abreast of the latest medical developments?
At Philadelphia CyberKnife, we are fortunate to be part of the latest radiosurgical developments and research. We have presented our data at international meetings and written papers and book chapters. My fellow doctors and I enjoy staying on the cutting edge of medical developments through our pursuit of clinical research.